Genmab | GEN - Selling And Administration Expenses


Genmab reported DKK205M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Amarin USD 18.97M 1.03M Dec/2025
Amgen USD 1.72B 134M Jun/2026
argenx SE USD 598M 181M Sep/2026
AstraZeneca USD 5.8B 735M Jun/2026
Bayer EUR 3.96B 267M Jun/2026
BioMarin Pharmaceutical USD 395.55M 137.27M Jun/2026
Demant DKK 7.09B 1B Jun/2026
Exelixis USD 147.63M 8.03M Jun/2026
Fresenius Medical Care EUR 736.01M 12.99M Jun/2026
Genmab DKK 205M 39M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
GN Store Nord DKK 805M 42M Jun/2026
GRIFOLS EUR 289M 8M Jun/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Insmed USD 247.47M 208K Jun/2026
Lakefront Biotherapeutics EUR 22.5M 13M Jun/2026
Merck EUR 1.57B 49M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.63B 307M Jun/2026
UCB EUR 1.47B 193M Dec/2025